Overview: Roche’s Next Move for Elevidys
Roche is pushing forward. Rather than relying on patient advocacy groups alone, the Swiss pharmaceutical giant is betting on clinical rigor. On April 16, 2026, Roche announced a new global Phase 3 trial for Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD). The goal is clear — generate the data needed to resubmit for European Medicines Agency (EMA) approval and expand access in other global markets.
Elevidys was developed by Sarepta Therapeutics, which holds U.S. rights to the therapy. Roche manages rights in all other regions. Today, the therapy is approved in nine countries for ambulatory boys diagnosed with confirmed DMD mutations.
Why the EMA Rejected Elevidys in 2025
A Negative Opinion That Stunned the Industry
In July 2025, the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Elevidys. Regulators concluded that the therapy had not demonstrated long-term benefits clearly enough to justify conditional marketing authorization.
The CHMP reviewed data from the pivotal EMBARK Phase 3 study. Although Elevidys did not meet its primary endpoint after one year, it showed statistically significant improvements on several secondary endpoints measuring motor function. Roche also submitted longer-term data — including two-year EMBARK results and a three-year pooled efficacy analysis. However, these were not sufficient to change the EMA’s position.
The Safety Controversy That Complicated Matters
The rejection did not happen in isolation. In 2025, Elevidys faced intense scrutiny after being linked to two patient deaths. The U.S. Food and Drug Administration temporarily paused shipments, and European clinical testing was also halted. Subsequently, the FDA placed restrictions on the therapy’s use in certain patient populations. Sarepta Therapeutics responded by laying off staff, scaling back gene therapy operations, and dramatically revising its once-multibillion-dollar sales projections downward.
What the New Phase 3 Trial Involves
Study Design and Patient Population
Roche’s newly announced Phase 3 trial will enroll approximately 100 early ambulatory boys with Duchenne muscular dystrophy. Participants will be randomized to receive either Elevidys or a placebo. The study will run for 72 weeks, focusing on measuring functional outcomes over a clinically meaningful period.
The Primary Endpoint: Time to Rise
The trial’s key measure is “time to rise” — the speed at which a patient can get up from the floor unassisted. This endpoint is considered an important predictor of disease progression in DMD. By choosing this outcome measure, Roche is aligning its evidence strategy directly with what regulators need to see before reconsidering approval.
Path to Resubmission
Roche confirmed that this study is specifically designed to generate the placebo-controlled data required for a formal resubmission to the EMA. Furthermore, the data is expected to support regulatory applications in other parts of the world where Elevidys has not yet received approval.
A Troubled Road: Controversies Around Elevidys
Elevidys holds the distinction of being the first approved gene therapy for Duchenne muscular dystrophy — a milestone years in the making. However, its journey has been far from smooth.
U.S. approval was initially based on mixed study results that raised questions about its clinical benefit. The subsequent deaths of two patients intensified scrutiny from regulators, patient groups, and the broader medical community. Throughout 2025, sales consistently declined. The therapy generated approximately $900 million in net product revenue that year, though Wall Street analysts have projected 2026 figures to fall well short of Sarepta’s own $500 million target. Taken together, these setbacks have made Elevidys one of the most debated gene therapies in recent memory.
Roche’s Confidence in Long-Term Data
Leadership Speaks Out
Despite the setbacks, Roche’s Chief Medical Officer and Head of Global Product Development, Dr. Levi Garraway, remains publicly committed to the therapy. He stated that confidence is rooted in robust, long-term data demonstrating durable efficacy and safety — backed by the experience of treating more than a thousand ambulatory boys worldwide.
The Broader Clinical Dataset
Elevidys has been studied in what Roche describes as the largest and most comprehensive gene therapy clinical development program in DMD history. Follow-up periods extend up to six years, covering patients of various ages and DMD mutation types. More than 900 individuals have been treated across clinical and real-world settings.
What This Means for Duchenne Patients
The Urgency Is Real
DMD is a rare, progressive genetic disease affecting primarily boys. It causes rapid muscle degeneration from early childhood. Eventually, patients lose the ability to walk, then lose upper limb, respiratory, and cardiac function. Average life expectancy for those with DMD is only around 28 years.
For families in Europe, where Elevidys remains unavailable following last year’s negative opinion, Roche’s new trial represents renewed hope. However, results from a 72-week study will take time. Moreover, regulatory review following any resubmission adds further months — possibly years — to the timeline.
A Critical Moment for Gene Therapy
Roche’s decision to proceed with another large-scale trial reflects the broader challenge facing gene therapies: achieving the level of evidence that regulators require while managing safety concerns in rare, fast-progressing diseases. The outcome of this trial will not only shape the future of Elevidys — it will also influence how regulators worldwide approach gene therapy approvals for rare pediatric conditions.
